Abstract
Original language | English |
---|---|
Pages (from-to) | 3008-3017.e4 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 10 |
Issue number | 11 |
Early online date | 2022 |
DOIs | |
Publication status | Published - Nov 2022 |
Keywords
- Academic productivity
- Allergic rhinitis
- MASK
- Mobile health
- Real-world data
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, No. 11, 11.2022, p. 3008-3017.e4.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Academic Productivity of Young People With Allergic Rhinitis
T2 - A MASK-air Study
AU - Vieira, Rafael José
AU - Pham-Thi, Nhân
AU - Anto, Josep M.
AU - Czarlewski, Wienczyslawa
AU - Sá-Sousa, Ana
AU - Amaral, Rita
AU - Bedbrook, Anna
AU - Bosnic-Anticevich, Sinthia
AU - Brussino, Luisa
AU - Canonica, G. Walter
AU - Cecchi, Lorenzo
AU - Cruz, Alvaro A.
AU - Fokkens, Wytske J.
AU - Gemicioglu, Bilun
AU - Haahtela, Tari
AU - Ivancevich, Juan Carlos
AU - Klimek, Ludger
AU - Kuna, Piotr
AU - Kvedariene, Violeta
AU - Larenas-Linnemann, D. sirée
AU - Morais-Almeida, Mario
AU - Mullol, Joaquim
AU - Niedoszytko, Marek
AU - Okamoto, Yoshitaka
AU - Papadopoulos, Nikolaos G.
AU - Patella, Vincenzo
AU - Pfaar, Oliver
AU - Regateiro, Frederico S.
AU - Reitsma, Sietze
AU - Rouadi, Philip W.
AU - Samolinski, Boleslaw
AU - Sheikh, Aziz
AU - Taborda-Barata, Luis
AU - Toppila-Salmi, Sanna
AU - Sastre, Joaquin
AU - Tsiligianni, Ioanna
AU - Valiulis, Arunas
AU - Ventura, Maria Teresa
AU - Waserman, Susan
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Zuberbier, Torsten
AU - Fonseca, João A.
AU - MASK study group
AU - Bousquet, Jean
AU - Sousa-Pinto, Bernardo
N1 - Funding Information: MASK-air has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA, and H2020) and educational grants from Mylan-Viatris, ALK, GSK, Novartis, and Uriach.Conflicts of interest: S. Bosnic-Anticevich reports grants from TEVA and personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Mylan. J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach, other from KYomed-Innov, personal fees from Purina, other from MASK-air. L. Cecchi reports personal fees from Malesci, Menarini, AstraZeneca, and Novartis. A. A. Cruz reports grants and personal fees from AstraZeneca, GSK, Sanofi; and personal fees from Boehringer-Ingelheim, Chiesi, Glenmark, Novartis, Mylan, and Abdi-Ibrahim. J. A. Fonseca reports participation in SME that has mHealth technologies for patients with asthma. J. C. Ivancevich reports personal fees from Abbott Ecuador, Bago Bolivia, Faes Farma, Laboratorios Casasco, and Sanofi. L. Klimek reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, and Sanofi; personal fees from HAL Allergie, Allergy Therapeut, and Cassella-med; grants from ALK Abelló, Stallergenes, Quintiles, ASIT Biotech, Lofarma, AstraZeneca, GSK, and Inmunotk; and is a member of AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV, GPA, and EAACI. V. Kvedariene reports other from Norameda and BerlinCHemie Menarini. P. Kuna reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Chiesi, GSK, Novartis, and Polpharma. D. Larenas-Linnemann reports personal fees from Allakos, Amstrong, AstraZeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, and Carnot; and grants from Sanofi, AstraZeneca, Novartis, Circassia, UCB, GSK, Purina institute, Abvvie, Lilly, and Pfizer. N. G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, and Boehringer Ingelheim; and grants from Gerolymatos International SA and Capricare. O. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., and GlaxoSmithKline; personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi-Aventis and Sanofi-Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc, RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, and Ingress Health; and grants from Pohl-Boskamp, Inmunotek S.L., Biomay, Circassia. J. Sastre reports grants and personal fees from Sanofi; and personal fees from GSK, Novartis, AstraZeneca, Mundipharma, and FAES Farma. A. Sheikh reports grants from Asthma UK. L. Taborda-Barata reports personal fees from AstraZeneca, GSK, Novartis, IQVIA/Abbvie, Mylan, Bial, Leti; and grants and personal fees from Teva. S. Toppila-Salmi reports personal fees from ERT, Roche Products, Novartis, Sanofi Pharma, AstraZeneca, and ALK-Abelló; and grants from Glaxo Smith Kline. I. Tsiligianni reports grants from GSK, Boehringer Ingelheim, and AZ; and personal fees from Novartis, AstraZeneca, and Chiesi. T. Zuberbier reports organizational affiliations: committee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA); member of the board: German Society for Allergy and Clinical Immunology (DGAKI); head: European Centre for Allergy Research Foundation (ECARF); president: Global Allergy and Asthma European Network (GA2LEN); member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: MASK-air has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA , and H2020) and educational grants from Mylan-Viatris, ALK, GSK , Novartis , and Uriach. Publisher Copyright: © 2022 American Academy of Allergy, Asthma & Immunology
PY - 2022/11
Y1 - 2022/11
N2 - Background: Several studies have suggested an impact of allergic rhinitis on academic productivity. However, large studies with real-world data (RWD) are not available. Objective: To use RWD to assess the impact of allergic rhinitis on academic performance (measured through a visual analog scale [VAS] education and the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific [WPAI+CIQ:AS] questionnaire), and to identify factors associated with the impact of allergic rhinitis on academic performance. Methods: We assessed data from the MASK-air mHealth app of users aged 13 to 29 years with allergic rhinitis. We assessed the correlation between variables measuring the impact of allergies on academic performance (VAS education, WPAI+CIQ:AS impact of allergy symptoms on academic performance, and WPAI+CIQ:AS percentage of education hours lost due to allergies) and other variables. In addition, we identified factors associated with the impact of allergic symptoms on academic productivity through multivariable mixed models. Results: A total of 13,454 days (from 1970 patients) were studied. VAS education was strongly correlated with the WPAI+CIQ:AS impact of allergy symptoms on academic productivity (Spearman correlation coefficient = 0.71 [95% confidence interval (CI) = 0.58; 0.80]), VAS global allergy symptoms (0.70 [95% CI = 0.68; 0.71]), and VAS nose (0.66 [95% CI = 0.65; 0.68]). In multivariable regression models, immunotherapy showed a strong negative association with VAS education (regression coefficient = −2.32 [95% CI = −4.04; −0.59]). Poor rhinitis control, measured by the combined symptom-medication score, was associated with worse VAS education (regression coefficient = 0.88 [95% CI = 0.88; 0.92]), higher impact on academic productivity (regression coefficient = 0.69 [95% CI = 0.49; 0.90]), and higher percentage of missed education hours due to allergy (regression coefficient = 0.44 [95% CI = 0.25; 0.63]). Conclusion: Allergy symptoms and worse rhinitis control are associated with worse academic productivity, whereas immunotherapy is associated with higher productivity.
AB - Background: Several studies have suggested an impact of allergic rhinitis on academic productivity. However, large studies with real-world data (RWD) are not available. Objective: To use RWD to assess the impact of allergic rhinitis on academic performance (measured through a visual analog scale [VAS] education and the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific [WPAI+CIQ:AS] questionnaire), and to identify factors associated with the impact of allergic rhinitis on academic performance. Methods: We assessed data from the MASK-air mHealth app of users aged 13 to 29 years with allergic rhinitis. We assessed the correlation between variables measuring the impact of allergies on academic performance (VAS education, WPAI+CIQ:AS impact of allergy symptoms on academic performance, and WPAI+CIQ:AS percentage of education hours lost due to allergies) and other variables. In addition, we identified factors associated with the impact of allergic symptoms on academic productivity through multivariable mixed models. Results: A total of 13,454 days (from 1970 patients) were studied. VAS education was strongly correlated with the WPAI+CIQ:AS impact of allergy symptoms on academic productivity (Spearman correlation coefficient = 0.71 [95% confidence interval (CI) = 0.58; 0.80]), VAS global allergy symptoms (0.70 [95% CI = 0.68; 0.71]), and VAS nose (0.66 [95% CI = 0.65; 0.68]). In multivariable regression models, immunotherapy showed a strong negative association with VAS education (regression coefficient = −2.32 [95% CI = −4.04; −0.59]). Poor rhinitis control, measured by the combined symptom-medication score, was associated with worse VAS education (regression coefficient = 0.88 [95% CI = 0.88; 0.92]), higher impact on academic productivity (regression coefficient = 0.69 [95% CI = 0.49; 0.90]), and higher percentage of missed education hours due to allergy (regression coefficient = 0.44 [95% CI = 0.25; 0.63]). Conclusion: Allergy symptoms and worse rhinitis control are associated with worse academic productivity, whereas immunotherapy is associated with higher productivity.
KW - Academic productivity
KW - Allergic rhinitis
KW - MASK
KW - Mobile health
KW - Real-world data
UR - http://www.scopus.com/inward/record.url?scp=85138100696&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2022.08.015
DO - https://doi.org/10.1016/j.jaip.2022.08.015
M3 - Article
C2 - 35998876
SN - 2213-2198
VL - 10
SP - 3008-3017.e4
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 11
ER -